A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-13. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
=== Variation === Considerable anatomic variation exists, in terms of length and point of attachment. Despite the classical description, the muscle only solely attaches to the duodenojejunal flexure in about 8% of people; it is far more common, 40 to 60% of the time to attach additionally to the third and fourth parts of the duodenum; and 20 to 30% of the time it only attaches to the third and fourth parts. Moreover, separate multiple attachments are not that uncommon. According to some authors, who use the original description by Treitz, the muscle may be divided into two sections: a ligamentous portion attaching the right crus of diaphragm to the connective tissue surrounding the coeliac artery and superior mesenteric artery; and a lower muscular portion from the connective tissue attaching to the duodenum. The superior portion is also described as the Hilfsmuskel. These two parts are now considered anatomically distinct, with the suspensory muscle referring solely to the lower structure attaching at the duodenum.
Polyvinylene carbonate is readily soluble in acetone and dimethylformamide. The solutions obtained, however, tend to decompose already at room temperature. The patent literature describes the use of polyvinyl carbonate for strong fibers, clear, colorless and mechanically strong films, membranes for reverse osmosis and as support during affinity chromatography. In addition to the instability in solutions, polyvinyl carbonate has the tendency towards hydrolysis in weakly alkaline medium. This forms polyhydroxymethylene (PHM) via cleavage of the cyclic carbon ring, with the repeating unit –(CHOH)–. Its behavior is much more similar to cellulose than to the structurally related polyvinyl alcohol with the repeating unit –(CH2–CHOH)–.
=== Editors === Francis Pharcellus Church (1859), editorial writer for the New York Sun and author of Yes, Virginia, There is a Santa Claus Horatio Sheafe Krans (1894), author and editor Simeon Strunsky (1900), literary editor of the New York Evening Post and editorial writer for The New York Times Lester Markel (1914), edited "Review of the Week", a section of The New York Times, which won the Special Awards and Citations Pulitzer Prize in 1953 Daniel Longwell (1922), co-founder and managing editor of Life Theodore M. Bernstein (1924), assistant managing editor of The New York Times Herbert Solow (1924), editor of Fortune Groff Conklin (1927), science fiction anthologist Emanuel Freedman (1931), foreign editor of The New York Times James Wechsler (1935), editorial page editor of the New York Post David Perlman (1939), former science editor of the San Francisco Chronicle Lester Bernstein (1940), former editor-in-chief of Newsweek Werner Wiskari (1941), international news editor of The New York Times Lucien Carr (1946), editor for United Press International Byron Dobell (1947), editor of American Heritage, Esquire; mentor to journalists Tom Wolfe, David Halberstam, and Mario Puzo Charles Peters (1949), founder and former editor-in-chief of The Washington Monthly Ashbel Green (1950), senior editor and vice president of Alfred A. Knopf Emile Capouya (1951), literary editor of The Nation 1969–1981 Robert Gottlieb (1952), editor of The New Yorker and president of Alfred A.
==== STS-118 ==== Caldwell Dyson was assigned to STS-118 on May 17, 2006. It was announced that she would serve as mission specialist 1 on the first flight of Space Shuttle Endeavour after the Columbia disaster. On August 8, 2007, Caldwell Dyson lifted off for the first time on the 119th Space Shuttle flight, the 22nd flight to the station, and the 20th flight for Endeavour. During the mission, she successfully added another truss segment, a new gyroscope and external spare parts platform to the International Space Station. A new system that enables docked shuttles to draw electrical power from the station to extend visits to the outpost was activated successfully. A total of four spacewalks (EVAs) were performed by three crew members. Endeavour carried some 5,000 pounds of equipment and supplies to the station and returned to Earth with some 4,000 pounds of hardware and no-longer-needed equipment. Traveling 5.3 million miles in space, the STS-118 mission was completed in 12 days, 17 hours, 55 minutes and 34 seconds. On day 7 of the flight of STS-118, Caldwell-Dyson celebrated her 38th birthday.
Sources: en.wikipedia.org
25 October – 485 people affiliated with the environmental group Bream Bay Guardians build sand sculptures to protest against a fast-tracked sand mining proposal in Bream Bay. 26 October: Police arrest an 18-year old Dunedin man in relation to a bomb threat against the Wellington Islamic Centre in Kilbirnie. Health NZ confirms a measles case at Wellington Girls' College. Four staff and 60 students are identified as possible contacts of the patient. 27 October: Two new measles cases are reported in Wellington, bringing the total number of cases to 10. One case were linked to international travel while seven were linked to a "high-risk exposure event" on a Bluebridge ferry on 3 October. Health NZ identifies several hundred close contacts at Wellington College. Waatea News reports that Te Pāti Māori members had voted to recommend the suspension of MP Mariameno Kapa-Kingi and that the Te Tai Tokerau electorate executive be "reset" at a meeting on 23 October. The New Zealand Government contributes NZ$150,000 to mayoral relief funds in Southland and Clutha District to assist with post-windstorm damage. Chinese citizens transiting through New Zealand become eligible for the New Zealand Electronic Travel Authority (NZETA). 28 October: The Labour Party unveils its capital gains tax policy to fund doctors' visits. Education Minister Erica Stanford releases the Government's full draft curriculum for Years 0–10 students for consultation. A power outage at a waste treatment plant in Warkworth contaminates oyster farms in the Mahurangi River.
== System components == A typical laboratory FPLC consist of one or two high-precision pumps, a control unit, a column, a detection system and a fraction collector. Although it is possible to operate the system manually, the components are normally linked to a personal computer or, in older units, a microcontroller.
The dangers of radium were recognized in the early 1920s and first described in 1924 by New York dentist and oral surgeon Theodor Blum (1883-1962). He was particularly aware of the use of radium in the watch industry, where it was used for luminous dials. He published an article on the clinical picture of the so-called radium jaw. He observed this disease in female patients who, as dial painters, came into contact with luminous paint whose composition was similar to Radiomir, a luminous material invented in 1914 consisting of a mixture of zinc sulfide and radium bromide. As they painted, they used their lips to form the tip of the phosphorus-laden brush into the desired pointed shape, and this is how the radioactive radium entered their bodies. In the U.S. and Canada alone, about 4,000 workers were affected over the years. In retrospect, the factory workers were called the Radium Girls. They also played with the paint, painting their fingernails, teeth and faces. This made them glow at night to the surprise of their companions.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.